leprae,the aetiological agent of leprosy in humans, gives rise to a chronic granulomatous disease that affects primarily the skin and peripheral nerves, and secondarily some internal organs such as the testis and the eye; viscera are seldom involved. Depending on host resistance, leprosy may present as a benign disease (tuberculoid leprosy) or as a malignant disease (lepromatous leprosy), with a spectrum of intermediate stages appearing between the two. Immunity against leprosy depends on the cell-mediated immunity of the host, and this is severely compromised in the malignant (lepromatous) form of leprosy. Although culture of M. leprae has never been achieved in artificial media, the bacterium may be grown in several experimental animals, including the armadillo, non-human primates, and to a certain extent, rodents. Naturally acquired leprosy has been reported in wild nine-banded armadillos (Dasypus novemcinctus) and in three species of non-human primates (chimpanzees [ Murine leprosy is a leprosy-like disease of rats and mice, caused by Mycobacterium lepraemurium. The disease affects primarily viscera and the skin, and very rarely peripheral nerves. Depending on the host strain, rodent leprosy may also evolve as 'lepromatous' or 'tuberculoid' leprosy, and strains of mouse that develop intermediate forms of the disease may exist. Growth of M. lepraemurium on conventional media for mycobacteria is not successful, but the bacterium has been cultured on an egg yolk-based medium. Naturally acquired murine leprosy has been observed in rats, mice and cats, but not in humans or any other species. Thus, in contrast to human leprosy, murine leprosy is not a zoonosis.
addition to kushtha) in India (600 BC) and as lai-ping in China (AD 281-AD 341). The name leprosy seems to appear for the first time in the Hebrew Bible in the year 300 BC and is synonymous with tsaraath.
Leprosy is described in medical treatises from India and China dating from approximately the 5th Century BC. The earliest evidence of bone involvement due to leprosy was found in a mummy in Egypt from the 2nd Century BC, and the first clear description of leprosy appears to be that found in Sushruta Samita, an ancient Indian book of medicine, where the disease is described as vat-rakta, vatasonita and kushtha by the year 600 BC. While vat-rakta and vatasonita are used to describe the disease characterised by hyperaesthesia, anaesthesia and deformities, kushtha described the disease characterised by skin ulceration, loss of fingers and sinking of the nose. Complementary descriptions of leprosy, recognising loss of eyebrows, development of nodules, absence of sweating, distortion of the ears and fingers, dim or blurred vision and blindness, appeared in medical treaties from China and other countries, between 600 BC and the beginning of the 6th Century AD.
Leprosy appears to have been introduced into Italy in the 1st Century BC, by Roman soldiers returning to Pompeii after fighting in Egypt. The disease spread throughout Europe during the Middle Ages, reaching a peak at the time of the crusades. Leprosy victims were so numerous that the disease was thought to be highly contagious, leading to the establishment of hundreds of leprosaria to protect the population from infection. The first leprosaria were founded in Nottingham, England (AD 625-AD 638), St Gallen, Switzerland (AD 720), Palenca, Spain (AD 1067), Bergen, Norway (1400), Culion, the Philippines (1906), and several locations in Japan (1907); many others followed. Commitment to a leprosarium was for life, and leprosy •became known as the living death. In France, for instance, such was the fear surrounding the disease that people were buried alive, burnt at the stake, or simply sent out with a bell and sometimes a candle. Philip IV (1285-1312), King of France, ordered that all persons with leprosy be gathered together and burned, and that the practice should continue until the disease was eradicated.
Leprosy seems to have reached the Americas between the 16th and 18th Centuries, via the European conquistadors and the slave trade.
For reasons not well understood, but probably related to improvement in health services and education, leprosy began to decline in Europe in the 15th Century AD. However, at the end of the 19th Century, leprosy was still endemic in Norway and in some areas of the Mediterranean basin. It was in Norway, in 1873, that Dr Gerhard Armauer Hansen discovered the bacillus that causes leprosy (96, 97) .
The disease
Leprosy or Hansen's disease, is a chronic, granulomatous disease of humans, caused by a slow growing acid-fast bacillus, Mycobacterium leprae. The disease affects primarily peripheral nerves and the skin, and secondarily other organs and tissues such as the eyes, the mucosa of the nasal and upper respiratory tract and the testes. In peripheral nerves, the key targets of M. leprae art the Schwann cells. However, leprosy does not affect the central nervous system, perhaps because of the higher temperature at this location. Damage to sensory nerves leads to anaesthesia and when these nerves supply the extremities of hands and feet, the latter become vulnerable to burns and other injuries that can often result in the loss of fingers and toes, and sometimes hands and feet. When cranial nerve involvement occurs, sensorial damage to the eye may produce corneal anaesthesia and even blindness. When motor nerves are involved, various forms of paralysis such as 'dropped foot', 'dropped wrist', 'clawed hand' and lagophthalmos (inability to close the eyes) can result. Nerve damage may also lead to loss of hair (mainly alopecia of the eyebrows and eyelashes) and dysfunction of the sweat and sebaceous glands, which causes drying and cracking of the skin. Lesions in the skin may also lead to secondary infections.
Skin-testing using lepromin has often been used to diagnose this infection. The lepromin test is a skin reaction elicited by the intradermal injection of lepromin, an autoclaved suspension of bacilli-containing tissue prepared from lepromatous nodules. A positive test appears as an indurated inflammatory reaction larger than 5 mm in diameter, maximally developed within three to four weeks of injection of lepromin. The test indicates the ability of the subject to mount a specific cell-mediated immune response to the antigens of M. leprae.
Depending on host resistance, leprosy presents a broad spectrum of clinical manifestations, ranging from one or a few lesions to widespread multiple nodules. All forms of leprosy appear to develop from a mild infection called indeterminate leprosy (283) .
Indeterminate leprosy
Indeterminate leprosy (IL) consists of single or multiple slightly hypopigmented or faintly erythematous and indefinite macules on the skin. Sensation, sweating and hair growth in the affected area are unaffected, as are peripheral nerves. Slit-skin smears are mostly bacilli-negative and the lepromin test may be either positive or negative. Indeterminate leprosy is usually self-healing, but may progress to other forms of leprosy.
Tuberculoid leprosy
Tuberculoid leprosy (TT) presents as a single or a few asymmetrical, reddish or hypopigmented lesions on the skin that appear to be dry and well demarcated by a raised edge; sensory loss is also reported in the area of the lesions (Fig. D- A few bacilli may be found*in skin biopsies, but slit-skin Borderline leprosy Borderline leprosy may be subdivided into borderline-tuberculoid (BT), mid-borderline (BB) or borderline-lepromatous (BL) leprosy. Depending on the position in the borderline spectrum, macular and other lésions vary greatly in number, size and shape. Hence, when the disease is nearer to the lepromatous leprosy (LL) end of the spectrum, the lésions are more numerous, shiny, bacilliferous and less anaesthetic. Bacilli are frequently found in the lésions, and numbers increase from very few in the BT lésions to many in the BL lésions. The lepromin test is generally négative, which indicates depressed cell-mediated immunity. The most severe damage to nerves is observed in this type of leprosy.
Lepromatous leprosy
Lepromatous leprosy is a inalignant form of the disease which may présent three -varieties, namely: macular, nodular or diffuse (Fig. 2) . Macules are small, multiple and symmetrical, with smooth shiny surfaces and very indistinct margins, they are faintly erythematous, not anaesthetic and contain bacilli.
The infiltrated skin of diffuse leprosy is thickened, erythematous and shiny, with slight or insignificant anaesthesia in the infiltrated areas. Bacilli are abundant, and alopecia of eyebrows is a common finding.
Nodular lésions of LL leprosy appear on the ears, face, extremities, trunk, and occasionally on genitalia. The lésions may be erythematous or skin-coloured, small or large, fairly hard and bacilliferous. Lepromatous patients are lepromin-negative and specifically anergic to M. leprae in lymphoproliferative assays in vitro. Cellular anergy to M. leprae in LL leprosy accounts for the systemic dissémination of the disease; M. leprae is found throughout the body, in lachrymal sécrétions, nasal mucus, sputum, breast milk, blood, semen and faeces.
Thus, résistant individuals develop paucibacillary (TT and BT) leprosy, while poorly résistant persons develop multibacillary (LL and BL) leprosy. Résistance or susceptibility to leprosy dépends on several known and unknown factors, including genetic and immune mechanisms (as discussed below).
Leprosy is regarded as the least contagious of ail of the infectious diseases, and the period from initial infection to onset of disease lasts from two to ten years. The shortest incubation time, of two months, was reported in a two-month-old girl who developed IL leprosy (83) .
people affected (165), followed by Africa (the WHO African region), which had the second highest prevalence, at one per 1,000 people. The global number of registered cases in the WHO African region was close to 480,000 (48) .
Aetiology
For centuries, leprosy was regarded as divine punishment for the sin of inappropriate behaviour. Leprosy was also considered a hereditary dyscrasia induced by eating hot food, pepper, garlic and the meat of diseased pigs and fish. The infectious nature of leprosy was recognised in 1749 in the Chinese medical classic Golden Mirror of Medicine (240) , which cited contact with those affected by leprosy, or with the houses or belongings of these people as infectious causes. However, in Norway, the renowned leprologist Danielssen, who discovered the 'brown bodies' characteristic of leprosy (now recognised as 'globi' or conglomerations of leprosy bacilli) regarded leprosy as a non-contagious 'hereditary dyscrasia sanguinis'. This was probably as a result of his several failed attempts, performed between 1844 and 1856, to transmit leprosy by inoculating himself and several volunteers with leprous material (see below). The infectious nature of leprosy was finally established in 1873 in Bergen, Norway, when Hansen discovered the 'rod-shaped bodies' of the leprosy bacillus (96, 97) . Hansen was aware that evidence for an infectious agent, based on microscopical observations in tissues, would be significantly strengthened by the isolation of the germ in culture and transmission of the disease by inoculating humans and animals with material from the tissues of leprosy patients (152) .
The leprosy bacillus
Based on biochemical, morphological and bacteriological characteristics, the leprosy bacillus was finally classified as M. leprae. When stained by the Ziehl-Neelsen procedure, M. leprae is an acid-fast, slightly curved bacillus, 0.3 pm-0.4 pm X 4 pm-7 pm in size, sometimes showing a metachromatic granule either near to a pole or in the centre. Within histiocytes, leprosy bacilli frequently aggregate in globi, the organisms being ordered into parallel bundles. The acid-fast character of the bacillus has been shown to be related to the cell wall, in particular to mycolic acids. One of these lipids, phenolic glycolipid-1 is regarded as specific for M. leprae and has been used in assays to diagnose the disease, to identify household contacts with incipient disease and to monitor patients undergoing chemotherapy (104, 221) . Arabinogalactan, arabinomannan, lipoarabinomannan and peptidoglycan, are among the other components present in the thick cell wall of M. leprae.
Transmission of Mycobacterium leprae
Untreated LL patients may discharge many millions of leprosy bacilli from nasal secretions every day, and the bacilli may survive for several days. The inhalation of bacilli-laden droplets is regarded as the most likely mode of entry of leprosy bacilli; bacilli have been detected in the nasal mucosa of household contacts of multibacillary patients and damage to the nasal mucosa is a facilitating factor (274, 279 (241) . The growth of M. leprae on medium LA-3 incorporated in agar (LA-3P) yielded small orange-yellow colonies in two to three weeks. Identification of the cultured bacilli as M. leprae was based on several weak observations, including similar isolations from different patients, failure to grow on the usual media for mycobacteria, and reactivity of the harvested micro-organism with fluorescein isothiocyanate-coupled anti-M. leprae antibody.
In 1988, Dhople et al. observed limited in vitro multiplication of M. leprae in a conditioned medium used for the growth of mouse (Mus musculus) dorsal root ganglion, after sixteen weeks of incubation at 34°C (59). The harvested bacilli were able to grow in mouse footpads, but subculture of the micro-organism in the same artificial medium was not achieved.
In 1989, Biswas reported development of a visible colony of M. leprae on the surface of Dubos-Lowenstein-Jensen medium supplemented with thyroxin, after sixteen weeks of incubation at 37°C (22). Inoculation of the bacterial suspension into the footpad of a cortisone-treated mouse produced a lesion with infiltration of nerves by lepra cells.
Successful growth of M. leprae was also reported in 1990 by Ishaque, after eighteen to twenty-four weeks of culture on an artificial medium, in a gas mixture containing 2.5% O 2 and 10% C0 2 (105) . The cultivated micro-organism was able to grow in mouse footpads, but lost viability after thirty-six weeks of culture. Three years later, Ishaque and Sticht reported that addition of palmitic acid to the above medium allowed the growth of M. leprae after sixteen to twenty weeks of incubation at 37°C, even in the absence of the gas mixture (106).
Dhople and Lamoureux, in 1991, were able to grow M. leprae in vitro, in the artificial Dhople-Hanks (DH) médium, in the présence of reduced concentrations of air (oxygen), and also found that M. leprae was microaerophilic (60) . The same year, Dhople reported that addition of carboxylated sulphydryl compounds and dithiothreitol to DH médium would allow maximum multiplication of M. leprae (58) . However, no proof was supplied to authenticate that the micro-organism grown in vitro was M. leprae.
In a more récent paper, Dhople and Lamoureux reported successful multiplication of M. leprae in DH médium supplemented with either cell-free extracts of armadilloderived M. leprae or extracts from irradiated livers and spleens of M. leprae-infected armadillos (61) . However, this multiplication was not achieved when the médium was supplemented with liver and spleen extracts from normal armadillos, and the authors suggested the existence of a growth factor in armadillo-grown M. leprae.
Despite thèse and other claims of successful cultivation of M. leprae in vitro, growth of M. leprae in a convincing and reproducible manner has never been achieved.
Immunology

Basic mechanisms of immunity
Protective anti-mycobacterial immunity dépends on co-ordinated lymphocyte and macrophage activity. Upon phagocytosis, macrophages initiate the killing and dégradation of ingested mycobacteria and the synthesis and sécrétion of cytokines, such as interleukin (IL)-1, IL-6, IL-12 and tumour necrosis factor alpha (TNF-a). Macrophages conclude the microbial processing by exposing a diversity of microbial epitopes on their cell membrane, in the context of major histocompatibility complex (MHC)-I or MHC-II molécules. Thèse membrane-exposed epitopes are recognised by reactive T cells (178) , which under the influence of macrophage-derived factors, proliferate and secrète a wide array of new cytokines. Depending on the reacting T cell, the resulting response may be humoral, cell-mediated, cytotoxic or suppressive immunity (Fig. 3) . Activation of T helper (TH)1 cells induces prolifération and sécrétion of gamma interferon (IFNy) and IL-2, among other cytokines, while activation of TH2 cells results in the prolifération and sécrétion of IL-4, IL-6, IL-10 and other cytokines (35, 173, 175) . In vitro, IFNy suppresses the antigen-induced prolifération of TH2 cells (78) , while IL-4 and IL-10 inhibit the antigen-induced prolifération of TH1 cells (174) (Fig. 4) .
Macrophage-derived IL-12 is a key co-stimulatory molécule for TH1 cells. This cytokine stimulâtes TH1 cells to synthesise IFNy and other cytokines (144) . In turn, IFNy stimulâtes the synthesis of TNF-a (a cytokine) in macrophages. This TNF-a autocrinally stimulâtes macrophages to produce nitric oxide, a potent cytotoxic metabolite, which is able to kill ingested and intracellular micro-organisms, including M. leprae (144) (Fig. 5) . In contrast, activation of TH2 cells induces the synthesis of IL-4, IL-6, IL-10 and other cytokines by thèse cells. Thèse cytokines stimulate B cells to produce high levels of antibodies, specifically the immunoglobulins IgGl and IgE (41) . The TH1 cells, through IFNy, also weakly induce B cells to synthesise immunoglobulins, in this case IgG2a (245) . Humoral immunity is generally protective against extracellular micro-organisms, but is not protective against intracellular mycobacteria.
The rôle of TH1 and TH2 cells and cytokines in leprosy The balance between TH1 and TH2 cell functions détermines the outcome of infection with M. leprae. The most obvious contrasting feature between LL and TT leprosy is the lack of M. ieprae-specific cell-mediated immunity in LL leprosy and the fully operating cellular immunity in TT leprosy. Since 1970, extensive work has been performed to discover the reason for the cellular anergy in leprosy. At présent, attention is focused principally on the rôle of TH1 and TH2 cell subpopulations (166, 167) . Thèse cells originate from a common precursor cell named THO, a CD4 + lymphocyte (CD: cluster of differentiation), which under undeciphered routes of differentiation, is transformed into either a TH1 or a TH2 lymphocyte. Activation of TH1 cells promûtes cell-mediated immunity, whereas activation of TH2 cells reinforces humoral immunity (34) . Despite the lack of spécifie cell-mediated immunity, LL patients présent a strong humoral antimycobacterial response. However, antimycobacterial antibodies are not protective, on the contrary, thèse antibodies hâve been involved in the development of type-2 (acute inflammatory downgrading) leprosy reactions, including erythema nodosum leprosum and necrotising vasculitis or Lucio's phenomenon (231, 283) .
Several research groups hâve analysed the cytokine pattems expressed by T cells in both the lésions and blood of TT and LL leprosy patients. Cytokines are believed to play immunoregulatory rôles both in host protection and immunopathogenesis of the disease. On this basis, recombinant cytokines hâve been used for the expérimental upregulation of the malignant disease (LL), with some success (239) . The TH1 cells and THl-type cytokines (IL-2 and IFNy) are generally associated with résistance to infection (TT macrophages (e) and this cytokine, in tum, upregulates the synthesis of iNOS (f) within thèse cells. This enzyme promûtes arginine metabolism from which citruline and the toxic metabolite nitric oxide are produced (g). Nitric oxide, acting both autocrinally and paracrinally, médiates the killing of intracellular bacteria leprosy), whereas TH2 cells and TH2 cytokines (IL-4 and IL-10) are associated with progressive (LL) disease (166, 226, 235, 236) .
In response to M. leprae, T cells from TT patients produce high levels of IFNy and low levels of IL-4 (95) . The same result is obtained on analysis of the reverse transcriptase-polymerase chain reaction (RT-PCR) products from ribonucleic acid (RNA) extracted from the lesions of TT or LL leprosy. Higher expression of genes for IFNy and IL-2 is observed in TT leprosy, while preferential expression of genes for IL-4, IL-5 and IL-10 is observed in LL leprosy (164, 282) .
In other studies, injection of recombinant IFNy or IL-2 into the lesions of LL leprosy induced local reversion of the anergy to M. leprae and promoted the healing of the lesions. In 1986, Nathan et al. intradermally injected 1 pg-3 pg of recombinant (r)IFNy, over a period of three days, into single skin lesions of six patients with LL leprosy, and six days later collected biopsies for histopathological analysis (185) . The rIFNy induced local changes characteristic of a cell-mediated immune response, including mononuclear cell infiltration, a decline in the number of epidermal Langerhans' cells, increased expression of the human leucocyte antigens HLA-DR, and in some cases, a reduction in the number of intralesional bacilli. In a similar study of seven LL patients in 1997, Villahermosa et al. injected several doses of rIL-2 into five lesions on the back. Twenty-one days later, the development of delayed-type hypersensitivity reactions was observed, including erythema and induration, infiltrates rich in CD4 + cells, monocytes and Langerhans' cells, and epithelioid granulomas at the sites receiving the highest doses (150 pg) of rlL-2 (268) . Some patients showed favourable shifts in histological classification or bacterial load. With the same idea, Kaplan et al., in 1988, intradermally injected twelve LL patients with a angle dose of 5 IU of purified protein derivative (PPD) and twenty-one days later collected biopsies from injected and control sites (116) . Eight out of ten patients that gave a positive PPD reaction (12 mm-21 mm) showed a marked mononuclear cell infiltrate, an increased number of CD4 + T cells compared to CD8 + T cells, and extensive destruction of the previously parasitised macrophages. A comparable response to the injection of rIL-2 was observed by Giedlin and Zimmerman in 1993 (82) , who observed that relatively low doses of IL-2 reversed the course of LL leprosy towards the benign TT pole. Thus, administration of PPD, IL-2 or IFNy into the lesions of multibacillary LL patients induces upgrading changes that include normal skin reactions, mononuclear cell infiltration, macrophage activation and bacilli elimination (115, 117) . 
Cytotoxic CD4 + T cells
In addition to endowing macrophages with the capacity to kill mycobacteria (150, 193) , activated CD4 + T cells also kill mycobacteria-containing macrophages, and the protective role of these cells can be induced by bacillus Calmette-Guérin (BCG) vaccination (112, 113, 177, 179) . Furthermore, activated cytotoxic CD4 + T cells release granulysin and perforin, proteins which are able to directly kill extracellular mycobacteria (252) .
Cytotoxic CD8 + T cells
Activated CD8 + T cells are MHC-I-restricted cytotoxic cells (120) whose principal role in anti-mycobacterial immunity appears to be to kill macrophages in granulomas that still contain bacilli (72) . Like cytotoxic CD4 + T cells, CD8 + T cells are also able to kill extracellular mycobacteria through the secretion of granular proteins (121) . The CD8 + T cells display a peripheral distribution in tuberculoid granulomas and an intermixed distribution in lepromatous granulomas (168) , this might suggest that these cells have a bacilli-confining role in TT leprosy and reflect the lack of organised immune response in LL granulomas. Alternatively, CD8 + T cells might be cytotoxic (protective) cells in TT granulomas and suppressor T (anergy-sustaining) cells in LL granulomas.
Gamma/delta receptor T cells
Over 95% of T cells carry the alpha/beta T cell receptor (TCRaB), and the remaining 3%-5% carry the gamma/delta T cell receptor (TCRyô). Furthermore, Tyô cells expand considerably during the acute phase of tuberculosis as a result of interaction with small phosphorylated mycobacterial antigens (230, 263) . Upon activation, Tyô cells release pro-inflammatory cytokines that provide the host with additional protective immunity (52) . A protective role for Tyô cells in leprosy is suggested by the fact that TT patients harbour greater numbers of circulating Tyô cell precursors than LL patients (12, 99) . Also, stimulation of blood mononuclear cells with M. tuberculosis results in a greater increase in the number of Tyô cells in TT (32%) than in LL (9%) patients (2) . In addition, early, two-day lepromin reactions in BL patients contain low numbers of thèse cells (± 4.4%), which increase more than three-fold (to ± 16%) at the time of maximal skin-reactivity (twenty-one days) (75, 76, 169).
CD1-restrictedT cells
CDI-restricted CD4 + T cells recognise unusual (lipid) mycobacterial antigens presented by antigen-presenting cells (mostly dendritic, CD83
+ cells), in the context of CD1 molécules (15, 16) . The CD1 molécules are strongly expressed in dermal TT granulomas, but are only weakly expressed in LL granulomas. However, TT and LL patients harbour comparable levels of circulating CDI-restricted T cell precursors (237) . The CD4 + CDl-restricted T cell linesderived from the lesions of leprosy patients are able to recognise mycobacterial antigens and, in response, release IFNy and granulocyte-macrophage colony-stimulating factor, but no detectable IL-4. Mycobacterium ¡eprae-reactive CD4 + CDl-restricted T cells that produce a THl cytokine pattern may play an important role in immunity to leprosy (238) .
Dendritic cells
Dendritic cells are regarded as highly efficient, antigen-presenting cells (237) , which are able to induce long-lasting, THl-dependent anti-mycobacterial immunity. This immunity is achieved through the sustained secretion of IFNy, a cytokine known to activate macrophages (and NK cells) (62) . To date, no conclusive studies exist regarding the quantities or function of these cells in LL or TT leprosy (Fig. 6 ).
Natural killer cells
The role of NK cells in anti-mycobacterial immunity has been deduced from the following observations: a) NK cells are able to kill heavily parasitised macrophages while simultaneously stimulating the microbicidal activity of those macrophages with smaller parasitic loads (170) b) cytotoxic activity of NK cells in TT leprosy can be induced by the stimulation of peripheral blood mononuclear cells with mycobacterial antigens (112, 113) , perhaps through the THl-derived secretion of IFNy and IL-2 c) lepromatous patients have circulating NK cells whose cytolytic activity is stimulated by M. leprae in the presence of IL-2 (36).
Immunology: a summary
Thus, clinical and experimental evidence indicate that cellular immunity to M. leprae is functional and is efficiently expressed in TT leprosy. Tuberculoid patients respond strongly to intradermally injected lepromin (Mitsuda reaction), but harbour low levels of anti-M. leprae antibodies. This suggests that the following is true of TT leprosy: a) cellular immunity is more efficiently induced than humoral immunity b) activation of THl cells requires lower antigenic doses (a few bacilli) than activation of TH2 cells, as has been demonstrated with attenuated M. bovis (BCG) in mice (199) c) activated THl cells inhibit activation of TH2 cells.
In contrast, for LL leprosy, specific cell-mediated immunity is completely absent, while humoral immunity is highly elevated. The reason for this cellular anergy in LL leprosy is not clear. However, several possibilities may be envisaged, as follows: The activity described in d) is predominant once the disease has definitively become established.
Supposing the existence of a single strain of M. leprae (not proved because of the inability to grow this micro-organism in vitro), the outcome of the disease as TT or LL leprosy would probably depend on the participation of host-specific genetic factors.
Susceptibility/resistance: genetic factors
Genetic factors linked to the major histocompatibility complex (human leucocyte antigen)
Attempts to identify genetic factors responsible for susceptibility to leprosy have been underway for many years. Some authors have suggested the existence of a HLA-linked genetic influence on susceptibility to leprosy. For instance, Todd et al. (261) discovered that HLA-DR2 and HLA-DQwl antigens were equally associated with both the LL and the TT forms of leprosy (relative risks: 2.65 for DR2 and 2.73 for DQwl). Others have found no direct link between HLA genes and susceptibility to leprosy per se, although significant associations have been reported between HLA-DR3 and TT leprosy, and HLA-DQwl and LL leprosy (57) . A marked association of DR2 with TT leprosy was reported by Dessoukey et al. in a study with leprosy-affected siblings (56) . An excess of DR2/DR2 homozygous individuals was found among TT siblings and the authors concluded that although susceptibility to leprosy per se may be due to non-HLA linked genes, DR2-homozygous individuals may be at a relatively high risk of developing leprosy or TT leprosy.
A positive association between DR2 specificity and TT leprosy (frequency: 56.3%; relative risk: 4.2), but not the LL, borderline or IL forms, was also found in a population in south Brazil by Visentainer et al. in 1997 (269) . In a study in Indonesia, while susceptibility to multibacillary (LL/BL) leprosy was found to be associated with HLA-DRB1*02 (attributable risk: 41.5%), resistance to the disease was associated with HLA-DRB1*12 (246) . In a similar study with leprosy patients from north India, a strong association was observed between the DRB1*1501 allele (a subset of the serologically defined DR2) and LL leprosy (203) . The much stronger association of DRB1*1501 with LL rather than TT leprosy suggests a possible role of this allele in the differential immune response to M. leprae. Thus, DR2 alleles or subtypes appear to be closely linked to susceptibility to leprosy in general, and to TT leprosy in particular. In association with HLA-DQ1 antigens, HLA-DR2 antigens may play a critical role in the entrance of mycobacteria into macrophages and/or in macrophage-dependent peptide presentation to THl cells.
Genetic factors not linked to the major histocompatibility complex
In the mouse, resistance or susceptibility to infection with mycobacteria seems to be controlled by the natural resistance associated macrophage protein 1 (NRAMP1) gene. This gene codes for an endosomal/lysosomal protein of the macrophage, which is rapidly incorporated into the phagosome membrane upon phagocytosis (88) . The function of this protein has been related to the acidification of the phagosome (93) , to metal ion transportation (288) , and to the transport of nitrogen (and nitric oxide) into the phagosomal milieu (30, 267) . Although recent genetic studies have suggested that allelic variants at the human NRAMP1 locus are associated with susceptibility to leprosy (1), other studies have not supported this theory (215, 224) . Susceptibility to leprosy is likely to be determined by several polymorphic genes that remain undefined at present.
Treatment
The discovery of the leprosy bacillus by Hansen, in 1873, initiated the long search for an effective treatment for leprosy. According to legend, many centuries ago a Burmese king who was suffering from leprosy was advised by the gods to eat the fruit of the Kalaw tree (Hydnocarpus) and was subsequently cured. Oil of chaulmoogra, extracted from the fruit, was commonly used until the 1950s, although without real success. However, based on several anecdotal reports claiming that leprosy patients taking capsules containing oil of hydnocarpus show faster wound healing than those not receiving the oil, Oommen et al., in 1999, undertook an experimental study to determine the effect of the oil in wounds experimentally inflicted on Wistar rats (192) . Animals treated with chaulmoogra oil showed a significant increase in body weight, degree of collagenation and strength of scar tissue. Oommen et al. concluded that the oil could be a useful adjunct in the healing of wounds and ulcers in leprosy patients (192) . A cure for leprosy was eventually discovered in 1943, in the form of the drug Promin; another treatment, diaminodiphenyl sulphone (DDS or dapsone) was discovered in 1947. However, the emergence of dapsone-resistant forms of leprosy (now affecting nearly 50% of the patients treated with this drug alone) and the discovery of newer antileprosy drugs, led to the implementation by the WHO in the early 1980s, of the more effective MDT. Multidrug therapy recommended by the WHO includes various combinations of drugs, namely: dapsone, rifampicin and clofazimine for multibacillary leprosy, and rifampicin and dapsone for paucibacillary leprosy. Conventional MDT consists of 600 mg of rifampicin and 300 mg of clofazimine (supervised) administered once a month, and the daily administration of 100 mg of dapsone and 50 mg of clofazimine (unsupervised). The duration of therapy is limited to six months for paucibacillary leprosy and two years for multibacillary patients. Relapse rates have been very low, 0.77% for multibacillary and 1.07% for paucibacillary, nine years after stopping MDT (280) . Since the introduction of MDT in 1982, a large reduction of registered cases has been reported, from 10-20 million in the mid-1980s to nearly 5.5.million in 1993 and 1.15 million in 1998 (281) . This is a considerable achievement, nevertheless, the number of newly detected cases has remained fairly constant over the same period, at approximately 600,000 per year. New drugs, including thionamide, fluoroquinolones, minocycline, clarithromycin and ofloxacin, among others, have been variably introduced into these multidrug regimens, with satisfactory results (162) .
Despite the impressive effects of MDT on the leprosy rate, the most effective method of arresting transmission of the disease is early detection and appropriate treatment.
Vaccines
Many attempts have been made to produce a vaccine against leprosy. The first reports refer to the use of M. bovis BCG, a vaccine known to be effective in at least some trials. 'Unfortunately, it has been found to be less effective in just those areas of the world where a vaccine is most needed' (248) . Although molecular biology offers the prospect of alternatives, no genetically engineered vaccine for field application has yet been produced, therefore the use of BCG is currently the only option (248) . Attempts to improve the efficiency of BCG against leprosy include mixing with heat-killed M. leprae (HKML), or administration in combination with MDT. Apart from BCG, other putative vaccines against leprosy are Mycobacterium w, M. vaccae, the Indian Cancer Research Centre (ICRC) bacillus and several of their extracted products (214) . Selected reports based on intact vaccines are discussed below.
Vaccines based on bacillus Calmette-Guérin
The first vaccine used to protect against leprosy was BCG. The BCG vaccine was used in five historic trials, with very variable results (189) . In the Uganda trial (started in 1960), 16,150 leprosy-contact children received the vaccine and 80% protection was reported eight years after vaccination. In the trial in Papua New Guinea (initiated in 1962), over 5,000 people were vaccinated, and protection of nearly 46% was reported after twelve years of follow-up. In the trial started in Burma in 1964, 28,220 children under fourteen years of age were vaccinated, and a minimal protection of 20% was reported after fourteen years of follow-up. In India (trial commenced in 1968), 210,337 people were vaccinated and moderate protection of 28% was reported after ten years of follow-up. In Malawi (trial started in 1974), 79,801 children under fifteen years of age received the vaccine and 57% protection was reported after twelve years of follow-up.
A recent study performed in Nagpur, India, indicates that protection against leprosy by BCG is more effective during the first decade of life, among females, and in the lower socio-economic strata (287). (91) . No significant differences in the lepromin results were observed within the different groups tested.
Bacillus Calmette-Guérin combined with heat-killed
In another study, a second vaccination with BCG appreciably increased the rate of protection against leprosy conferred by a single dose of BCG (119) . Addition of HKML did not improve the protection afforded by a primary BCG vaccination and the rate ratio for BCG with killed HKML versus BCG alone, among scar-negative individuals, was 1.06 for all ages.
Bacillus Calmette-Guérin combined with multidrug treatment
Majumder et al. administered MDT for two years combined with one to six doses of a mixed vaccine containing HKML and BCG, to thirty far-advanced, lepromin-negative, LL patients (151). Twenty similar patients were treated with MDT and BCG, and twenty control patients were only given MDT. The overall results indicated that within two years, all patients receiving MDT plus the vaccines, and nineteen of the twenty patients receiving only MDT, became clinically inactive and bacteriologically negative. Although the results were essentially similar in both groups of patients, those patients receiving the mixed vaccine therapy showed a more rapid clinical cure and clearance of bacilli than the patients in the other groups. In addition, conversion to lepromin positive responses was observed in 63% of the patients in the group given MDT, HKML and BCG, in 15% of the group given MDT and BCG and in 5% of the MDT group. In another study, Follow-up of patients was undertaken every three months for two years. All patients within the four groups showed clinical cure and were bacteriologically negative within two years. However, immunological potentiation, assessed by lepromin testing and the leucocyte migration inhibition lest, was better in patients receiving treatment a) compared to patients from the other groups.
Vaccines based on the Indian Cancer Research Centre bacillus
The ICRC bacillus is a micro-organism grown in vitra, originally isolated from a case of LL leprosy, and presently classified within the M. avium-intracellulare complex. This bacillus shares with M. leprae epitopes able to elicit cross-reactive cell-mediated immunity. The first attempt to protect against leprosy using the ICRC bacillus was performed by Deo et al. in 1990 (55) . Seventy-one LL patients, eleven BL patients, twelve leprosy contacts and twenty healthy non-leprosy contacts, all negative to lepromin, were inoculated with 10 9 , 10 8 , 10 7 and 10 6 killed ICRC bacilli, respectively. After ten months, a positive lepromin skin reaction was observed in 58% of LL patients, 91% of BT patients, 92% of leprosy contacts and 45% of non-contact individuals.
In another study which commenced in 1991 (92), 171,400 healthy people from a leprosy-endemic region were randomly allocated into five groups that were vaccinated with one of the following:
A survey in 1998 indicated protection rates of 64% (BCG with HKML group), 65.5% (ICRC group), 25.7% (Mycobacterium w group) and 34.1% (BCG group). The ICRC vaccine and the combination of BCG and HKML fulfilled the requirement for public health use and deserve further consideration. In a more recent study, Bhatki and Chulawala treated eight highly bacilliferous (bacterial index [BI] >4+) LL patients with a single dose of ICRC vaccine at the start of MDT (18). Eight similar patients received MDT alone. After two years of follow-up, an average reduction of BI was reported, from 4.4+ to 1+ in the ICRC-vaccinated group and from 4.7+ to 2.6+ in the group given MDT alone, a finding consistent with the expected response to MDT.
Vaccines based on Mycobacterium w
Mycobacterium w is a non-pathogenic, rapidly growing mycobacterium that shares a number of antigenic determinants with M. leprae and M. tuberculosis, and for this reason has been used as an alternative vaccine for these diseases.
In one representative study, autoclaved Mycobacterium w and MDT were administered to fifty-four multibacillary, lepromin-negative patients (258) . Thirty-seven similar patients received MDT and placebo injections. Vaccination was repeated every three months, and the effects were assessed after one year of follow-up. Bacterial clearance and clinical improvement were observed to be more rapid in the vaccinated patients. None of the multibacillary patients from the placebo group became bacteriologically negative during the survey. After four doses of the vaccine, 100% of BB, 85.7% of BL and 61.5% of LL patients became lepromin-positive. In a similar study, Kar et al. administered the Mycobacterium w vaccine to sixty-eight lepromin-negative multibacillary leprosy household contacts and registered the rate of conversion to lepromin positive responses (118) . A conversion rate of 98.5% (67/68) was reported, and conversion was determined to be permanent. Similar results were reported in 1993 by Zaheer et al. who applied the vaccine to a group of BL and LL patients treated with MDT (286) . Patients receiving the vaccine underwent rapid clinical improvement with an upgrading in the disease spectrum and accelerated bacteriological clearance of the granuloma. Of the BL and LL patients who received both the vaccine and MDT, 42% were bacteriologically negative after two years of treatment (versus 20% in the unvaccinated group). Lepromin conversions were observed in 80% of the patients in the vaccinated group and in only 14.3% of the unvaccinated patients.
Thus, as an adjunct to MDT, the vaccine expedites bacterial clearance and accelerates clinical regression of lesions. Vaccination significantly shortens the treatment period required, is effective in inducing a fall in the bacterial index in multibacillary patients and promotes the conversion of over 60% of LL, 71% of BL and 100% of BB patients from a lepromin negative to a lepromin positive status. A significant number of vaccinated patients show histopathological upgrading and eventually the attainment of a state of non-specific infiltration without dermal granulomas (257) . Similar properties have been recognised for M. vaccae by Stanford et al. (249) , and intradermal injection of heat-killed M. vaccae has been found to promote cell-mediated immunity to antigens common to all mycobacteria, including M. leprae and M. tuberculosis.
Experimental transmission to humans
In 1844, deliberate attempts to infect humans with leprosy were first recorded by Danielssen. However, these attempts were unsuccessful, as were others performed at that time (207) . Danielssen repeatedly attempted to transmit leprosy by inoculating himself and nine volunteers with leprous material, without success. In 1868, Profita and Cagnina inoculated themselves and eight volunteers with leprous material without causing leprosy (240) . In 1879, Hansen inoculated material taken from a lepromatous nodule into the eye of a thirty-three-year-old female patient suffering from a mild form of leprosy, without her consent. Although LL leprosy did not result, the experiment was impugned and the episode ended in a court of law, with the dismissal of Hansen from his post as a physician at the Leprosy Hospital, Bergen, Norway. However, because of the paramount importance of leprosy in Norway, Hansen retained his position as Chief Medical Officer for Leprosy (23). In Hawaii, in 1884, Aming inoculated a convicted murderer (with consent) with a freshly excised leproma; twenty-five months later, the subject showed disseminated nodular leprosy. In 1916, Mouritz reported attempts to infect fifteen consenting leprosarium assistants with leprous material without producing leprosy (207) . Effective accidental infection by finger prick was reported by Langen in 1933 (137) and also by Marchoux in 1934 (155) , while Porritt and Olsen in 1947 reported two men who developed leprosy in America, three years after being tattooed in the Philippines (197) . Deliberate self-inoculation leading to leprosy infection was also reported by Lagoudaky in 1937 (133) .
Experimental transmission to animals
The experimental transmission of leprosy has been researched in over fifty animal species. The following is a selected account of the many attempts so far performed.
Rabbits
Rabbits appear to be the first species sought as a possible animal model for leprosy, and the anterior eye chamber is the most utilised inoculation site, perhaps because this route of inoculation had proved successful for transmission of tuberculosis (Table I) .
Monkeys
Attempts to experimentally infect several species of monkeys with leprosy were first attempted at the same time as those in rabbits (Table II) .
Rodents
The first report on transmission of leprosy to mice appears to be that of Sugai in 1909 (111). Many other reports followed, including those by Shepard, who introduced the footpad model (233, 234), Rees et al. with thymectomised and irradiated mice (206, 209) , and Colston and Hilson (43) with congenitally athymic nude mice (Table III) .
Armadillos
The nine-banded armadillo (Dasypus novemcinctus), one of several species of armadillo, was first sought as a model for the study of leprosy by Storrs in 1971 (253) . The species is an inhabitant of the Americas and is found throughout South America and Central America and up to the south-east of the United States of America (USA). The rationale for considering armadillos as a potential leprosy model was' the low body temperature (32°C-35°C) and long life span, estimated to be fifteen years. Production of monozygotic quadruplet breeds was an additional bonus of this animal, as this offered the possibility of conducting genetic studies on the disease. This and other attempts to transmit leprosy to armadillos are summarised in Table IV .
Other species
In addition to rabbits, monkeys, rodents and armadillos, many other animal species have been used as prospective models of leprosy. Some of these are listed in Table V .
Experimental transmission: a summary
Experimental transmission of leprosy has been reported in most of the species tested, although birds, reptiles and amphibians have been clear exceptions. However, the definition of success has varied widely and whereas most (Fig. 7) , in normal mouse footpads, in congenitally athymic nude mice and rats, in Korean chipmunks (Eutamius sibiricus asiaticus), and in experimentally immunosuppressed mice and rats.
Naturally acquired disease in wild animals
Chimpanzees
Donham and Leininger reported a leprosy-like disease in a chimpanzee in 1977 (64). This primate was obtained from Sierra Leone, Africa, for a study on the susceptibility of chimpanzees to bovine leukaemia virus. Two months after inoculation with the virus, lesions suggestive of leprosy appeared on the face and ears of the chimpanzee. Biopsies taken from the lesions contained acid-fast bacilli that could not be cultured in conventional mycobacterial media. However, these bacilli produced a limited infection in mice, similar to that produced by M. leprae of human origin. Further studies undertaken over a twenty-one-month period on the same animal determined that the nodular lesions were characterised by diffuse dermal infiltration, foamy pale histiocytes containing acid-fast bacilli, loss of dermal collagen, except for a thin zone just beneath the epidermis, and affection of small dermal nerves, which appeared to be surrounded by histiocytes and dense collagen. Acid-fast bacilli were observed in the nerve and the cytoplasm of infiltrating histiocytes.
These clinical, histopathological and bacteriological findings were all compatible with LL leprosy (139) . This animal died thirty-three months after the first manifestation of leprosy. The findings at autopsy were diffuse histiocytic infiltrations of the skin, nasal mucosa, pharynx, lung interstitium, liver, spleen, sciera, testicles, adrenal glands and peripheral lymph nodes, extensive fibrosis of the major nerves of the forearm, and large quantities of acid-fast bacilli in the infiltrating histiocytes. The histopathological features of the disease and the overall characteristics of the acid-fast bacilli in the tissues corroborated the diagnosis of LL leprosy (140) .
By monitoring the antibody levels to phenolic glycolipid-I and lipoarabinomannan in the sérum of chimpanzees, Gormus et al. were able to detect two animais with high antibody levels to both antigens, suggestive of an ongoing, naturally acquired leprosy infection (85) . Thus, leprosy may exist in chimpanzees in the USA and may be transmitted among chimpanzees, and even to humans.
Mangabeymonkeys
Meyers et al. discovered naturally occurring leprosy in a mangabey monkey importée! from Africa, which had never been experimentally inoculated with M. leprae (160, 161) . Clinical signs of leprosy included diffuse and nodular infiltration of the ears,.face and forearms. Biopsies taken from thèse lésions contained large amounts of acid-fast bacilli and revealed histological features compatible with subpolar LL leprosy. The aetiological agent satisfied ail available criteria for identification as M. leprae, including invasion of nerves, differential staining, électron microscopic findings, non-cultivation in vitro, lepromin reactivity, infection patterns in mice and armadillos, sensitivity to sulphone, deoxyribonucleic acid (DNA) homology, and spécifie antibody response. In 1988, Gormus et al. described a second mangabey monkey with naturally acquired leprosy, whose clinical, histopathological and bacteriological characteristics corresponded to subpolar LL leprosy (84) . This monkey had been housed together with the first mangabey, in which naturally acquired leprosy was diagnosed in 1979. Clinical symptoms of leprosy appeared in the second mangabey almost seven years after détection of leprosy in the first monkey. The second mangabey may hâve contracted leprosy from the first monkey, or both animais may hâve contracted the disease from a common third source, perhaps a patient with active leprosy. This finding suggests a potential zoonosis in wild mangabeys that may serve as a réservoir for the disease in areas where leprosy is endémie.
Cynomolgus macaques
A case of naturally acquired leprosy was reported by Valverde et al. in 1998 , in a macaque imported from the Philippines (266) . The macaque developed a positive skin test to tuberculin after three years of captivity in the Califomia Régional Primate Research Center, USA, and showed cutaneous lésions suggestive of mycobacterial infection. Biopsies of the lésions were taken and subjected to histopathological examination and to molecular diagnoses by the polymerase chain reaction (PCR) spécifie for M. leprae. The clinical features of the disease and the results from the histopathological, PCR and serological studies, were ail compatible with BB leprosy.
Armadillos
A naturally acquired leprosy-like disease was detected in seven nine-banded armadillos captured from the wild in Southern Louisiana. Thèse animais were found to be afflicted with a disseminated disease involving several organs and nerves. Lésions in the diseased tissues (skin, nerves, lymph nodes, spleens and livers) contained macrophages full of acid-fast bacilli that did not grow on standard mycobacterial média (Lôwenstein-Jensen and Middlebrook 7H10) and were suspected to be M. leprae (270) . After this first report, forty-nine additional armadillos, captured in Louisiana, were reported to hâve the disease (272) . The histopathological and microbiological study of thèse animais revealed that the lésions were composed of macrophages containing numerous bacilli, similar to those observed in armadillos experimentally inoculated with M. leprae. Cultures on mycobacterial média of lymph node and spleen spécimens were négative for twenty-four of thirty-two armadillos, but. M. avium and M. intracellulare were cultivated from the remaining eight armadillos. The acid fastness of the bacilli in ail tissues was pyridine-extractable and the bacilli were dihydroxyphenylalanine (DOPA) oxidase positive. Thus, the histopathological and microbiological studies of thèse armadillos suggested that the infecting micro-organism was M. leprae (21).
Smith et al. confirmed a leprosy-like disease of wild nine-banded armadillos (243) . Of twenty armadillos captured in the wild in French Acadiana, Louisiana, USA, two had a leprosy-like disease that was indistinguishable from the disease experimentally produced in armadillos by inoculation with M. leprae (20, 106). The disease was also similar to that previously described in wild armadillos by Walsh et al. in 1975 (271) , and by Meyers et al. in the same year (159) .
More recent surveys of naturally occurring leprosy-like disease in wild armadillos have indicated a very significant global incidence of the disease, ranging from 1.0% to 15% in several areas investigated. Recent surveys were performed by Folse and Smith (73) , on the Gulf Coast of Texas, on 451 animals (4.66% infected), by Truman et al. (262) in Louisiana with 216 armadillos (2.7% infected), and finally by Job et al. in Louisiana with 494 armadillos (2% infected) (108) , and later with thirty-nine armadillos (3%-53.3% infected) (109) . This latter study was of particular interest because the several methods used to detect the leprosy infection in armadillos produced very different results; the histopathological study of ears revealed infection in 3% of the animals, the study of granulomas in the inguinal lymph node revealed infection in 6.7%, autopsy of the whole animal revealed a 13.3% infection, and the PCR study of inguinal lymph nodes indicated a rate of infection of 53.3%.
These findings of naturally acquired leprosy in armadillos strongly suggest that the disease in this animal is a true zoonosis. However, although the possibility that naturally infected armadillos could represent a source of infection for humans has been considered, definitive proof of this is still lacking. In a study to determine the association between contact with armadillos and the presence of leprosy in humans, contact between armadillos and people with indigenous leprosy in Louisiana was compared to the contact between matched healthy controls and armadillos. No difference in the nature or frequency of contact was found (69) . However, extensive contact with armadillos has been implied by other observers to be the cause of leprosy in several patients in Texas (244) .
Mycobacterium leprae in sphagnum mosses
While leprosy patients undoubtedly constitute the most common source of contagion and transmission of the disease, naturally infected animals or soil can also harbour the aetiological agent. Acid-fast bacilli containing M. lepraespecific phenolic glycolipid-I have been isolated from Sphagnum mosses from a former leprosy-endemic region of Norway (124) . These acid-fast bacilli multiplied in a limited manner in the footpads of normal mice, and multiplied by nearly ten-fold in the footpads of nude mice at sixteen weeks. The limited multiplication of the sphagnum-derived M. leprae-like mycobacteria, in both normal and nude mice, could be due to low pathogenicity of the micro-organism compared to the higher pathogenicity of M. leprae obtained from clinical cases.
Leprosy as a zoonosis
Natural infection by M. leprae has been described in two primate species from West Africa (the chimpanzee and the mangabey), in the cynomolgus macaque (Macaca fascicularis) in Asia, and in the nine-banded armadillo in the USA. Leprosy infection has also been experimentally established in armadillos, mangabeys, rhesus monkeys, African green monkeys and white-handed gibbons, following intravenous and intradermal inoculation of M. leprae. The experimental disease, in each case, strongly resembles leprosy in humans clinically, histopathologically and immunologically. Therefore, several non-human primates may serve as a zoonotic source of M. leprae (158, 162, 163, 273) .
Murine leprosy -
Mycobacterium lepraemurium
Since the 1940s when murine leprosy was abandoned as a model for human leprosy, few further studies of. this leprosy-like disease have been performed. Hence most of the current knowledge of the disease is derived from studies performed between 1903 and 1940. However, due to the fact that the mouse is the most popular laboratory animal, basic research on murine leprosy has remained a very productive activity. Murine leprosy is still being used as a study model to understand those cellular, molecular and genetic factors that render a host susceptible or resistant to-infection by intracellular mycobacteria similar to M. leprae (147, 216) .
History
Murine leprosy was first described in 1902 by V.K. Stefansky (250) , who found the disease in rats while working on a rat eradication campaign in the city of Odessa in the Ukraine. The following year, the disease was reported in England by Dean (50) and within a few years, cases were reported from other parts of the world (153) . The first descriptions of the disease by Stefansky (251) and Dean (50, 51) recognised a striking similarity between murine and human leprosy, both in terms of the causative organisms and in terms of the clinical and histopathological manifestations of the disease. These findings led to the belief that human and murine leprosy were identical or very closely related diseases (154, 156, 270) , and for several years, this was the major motivation for the study of murine leprosy. As a result, considerable attention was afforded to murine leprosy, both in clinical journals and public health reports (46, 47, 153) . The similarity between the two mycobacterioses was supported by the following:
a) studies demonstrating serological cross-reactivity between M. leprae and M. lepraemurium, the causative agent of murine leprosy (51, 229) h) reports that human leprosy had been transferred from humans to mice (111) c) reports on murine leprosy in humans (154) d) microbiological reports claiming that M. leprae and M. lepraemurium were identical or almost identical (270) .
However, as a result of improved knowledge of both the disease and the micro-organism, the idea that murine leprosy was a reservoir for human leprosy was gradually abandoned.
Murine leprosy as a model for the study of human leprosy
Despite the récognition that murine leprosy and human leprosy were not the same disease, the need to create a model for human leprosy persisted (210) . Expérimental infection with M. leprae in the mouse footpad was first described in 1960 (233) , but until then the only laboratory model for leprosy was murine leprosy. In contrast to M. leprae, M. lepraemurium has the clear advantage of being adéquate for expérimental use in the mouse as it is a natural pathogen in this species (129, 135) . In addition, Stefansky and Dean had already described polar forms of murine leprosy, with a broadly continuous spectrum in between the two pôles (51, 251) . The observation that expérimental murine leprosy in inbred strains of mice displayed the spectral pattern reported in human leprosy greatly strengthened the value of the murine leprosy model (39, 122, 123, 211) .
Murine leprosy and human leprosy are both naturally occurring chronic granulomatous diseases of mammals caused by acid-fast bacteria. The macroscopic and microscopic similarities between murine and human leprosy are striking and both illnesses are 'spectrum diseases'. Both M. leprae and M. lepraemurium were until recently regarded as non-cultivable and only since 1970 has M. lepraemurium been grown in vitro (191) . Both mycobacteria multiply very slowly in the host, with a doubling time of one to three weeks (26, 233) . Both are found predominantly in an intracellular location and appear to be essentially non-toxic to host cells (4, 51, 70, 153) . The two mycobacteria display structural similarities (51, 77) and show immunological cross-reactivity, as detected with antibodies (131) and in skin tests (186) . In both human and murine leprosy, a spécifie dépression of cell-mediated immunity appears to occur, but no dépression of humoral immunity (10, 40, 180, 216) .
However, several différences exist between human and murine leprosy. Mycobacterium leprae and M. lepraemurium are clearly différent species of bacteria (198) , and chemical, immunological and molecular DNA studies indicate that M. leprae and M. lepraemurium are as closely related to other mycobacteria as they are to each other (5,* 132). Mycobacterium leprae and M. lepraemurium are intracellular parasites of macrophages, but again show important différences. Both micro-organisms are captured and initially enclosed within phagocytic vesicles, but M. leprae disrapts the phagolysosomal membrane and escapes into the cytoplasm where the bacterium proliférâtes safely (171) . In contrast, M. lepraemurium résides within the phagolysosome (98) and seems to require a high concentration of lysosomal enzymes to multiply (4, 25) . Within macrophages, both M. leprae and M. lepraemurium appear to be surrounded by électron transparent zone material (ETZ), which in M. leprae is composed of spherical droplets of lipid material that is always liquid at body température. In M. lepraemurium, however, the ETZ is composed of ribbon-like or membranous structures that are solid or crystalline at the body température of mice (187) .
Unlike M. leprae, M. lepraemurium does not show great affinity for peripheral nerves, although both human and murine leprosy are granulomatous diseases affecting the skin (220, 259) (Fig. 8) . Nevertheless, depending on the host strain, a small percentage (l%-3%) of M. lepraemuriuminfected mice develop bilatéral paralysis of the rear limbs as a likely manifestation of nerve involvement (223) . 
Mycobacterium lepraemurium
Like M. leprae, M. lepraemurium is a slender rod-like acid-fast bacillus measuring 2 um-7 um in length and 0.3 um-0.4 um in width (Fig. 9) . For many years, growth of M. lepraemurium in vitro was not successful, and therefore this micro-organism was traditionally propagated by animal passages after isolation from infected wild rats or mice (a technique that is still in use). Some différences between strains of M. lepraemurium hâve been reported, both with regard to gênerai virulence and extent of skin involvement in infected animais (6), but no antigen différences hâve been observed (247) . 
Transmission
Under natural circumstances, transmission of murine leprosy is very likely to occur through abrasions in the skin and through the mucosal respiratory surfaces, as in human leprosy (110, 183, 276, 279) . Infection through the digestive surfaces is another possibility, as cannibalism is common among rats and mice. The thick and complex lipid coat of M. lepraemurium is very likely to resist the digestive effect of gastric juice.
Natural and expérimental disease
Few différences hâve been reported between natural and expérimental infection with M. lepraemurium. Skin involvement appears to be more common in natural rather than expérimental disease, and greater involvement of the viscera appears to occur in expérimental, compared to natural disease (130) . However, thèse différences could be due to the larger inocula used in expérimental infection.
The natural mode of transmission of murine leprosy has not been definitely established. However, the disease appears to start in the skin, mainly in those régions most exposed to scratches and bites (145) . The disease may also be transmitted by the respiratory route, just as in humans; the successful transmission of leprosy through nasal mucosa has been reported in the nude mouse. Attempts to transmit the disease experimentally by insects hâve been unsuccessful (145) , and rats fed infected tissue only rarely developed signs of disease (176) . Bacteria placed on newly shaved skin caused infection (153, 156) , and rats shaved and repeatedly rubbed with mud collected near houses where leprous rats were abundant developed 'soil leprosy', which could not be distinguished from ordinary rat leprosy (136) . Healthy rats placed in cages with rats infected with rat leprosy were found to develop murine leprosy (47) . Experimentally, a dose of five M. lepraemurium bacteria administered subcutaneously is reportedly sufficient to initiate infection (157) . Natural infections usually undergo a stage in which the primary defence barriers are broken, and the initial immune reactions will occur at a peripheral site. Expérimental infection with small doses of bacteria administered subcutaneously would therefore be expected to closely mimic natural infection. A différence between strains of M. lepraemurium with regard to skin involvement was reported by Badger and Fite in 1940 (6) , but no further data hâve been reported.
The species of expérimental animal may influence development of the disease. Murine leprosy affects approximately 5% of mice, and about the same percentage of rats (156) . Spontaneous musculocutaneous murine leprosy has been described in a wild mouse spécimen (129) . Using bacteria from this mouse, expérimental disease in mice and rats presented only minor différences between the species, some experimentally inoculated mice developed disseminated skin lésions resembling those in spontaneous disease (130) . Certain strains of rat are relatively résistant to viscéral infection, and develop leprosy that is more like human leprosy, with skin involvement, whereas other strains hâve a low tendency to affect the skin (94) . Nude mice (123) and hairless mice (194) develop extensive skin involvement after expérimental M. lepraemurium inoculation, which suggests that the immune System and possibly other genetic factors are important in determining whether involvement of the skin develops. Hairless euthymic (194) and hypothymic (222) mice are also susceptible to infection with M. lepraemurium. Intradermal or intraperitoneal inoculation of thèse animais with suspensions of M. lepraemurium produced a disseminated disease, similar to that observed in control hairy mice.
Murine leprosy in inbred mouse strains
Since the 1950s, inbred strains of mice hâve dominated work on expérimental murine leprosy. Comparative observations on the development of murine leprosy in various inbred strains of mice (C57B1, BALB/c and C3H) demonstrated that expérimental mouse leprosy can be classified as one of three clinical types, depending on the strain, namely: benign (C57B1), intermediate (BALB/c) and malignant (C3H) (122).
The highly inbred homozygous state is excellent for the identification of isolated genetic factors influencing résistance or susceptibility to infection and for obtaining reproducible in vivo expérimental results (146) . However, as emphasised by Rees and Weddell (210) , this is an artificial state and the use of outbred or even-wild mice may be required for the final test of the validity of expérimental findings.
Immunology
Mouse inbred strains are not equally susceptible to infection by M. lepraemurium; CH3 mice are more susceptible than BALB/c mice, and the latter are more susceptible than C57BL mice (38) . Murine leprosy infection in susceptible mice induces a progressive loss of non-specific immune responses, both cell-mediated (skin response to oxazolone or picryl chloride) and humoral (antibodies to sheep erythrocytes) (29, 201, 217) . Differences in the M. lepraemurium-specific cell-mediated immune response of susceptible and resistant strains of mice have also been observed. Early in the infection (two to four weeks), both susceptible and resistant mice develop delayed type hypersensitivity to M. lepraemurium antigens that correlates with the capacity of the splenocytes to proliferate in vitro in response to the microbial antigens (24). Differences between susceptible and resistant strains become evident at four weeks after infection. Susceptible animals start to show progressive loss of the capacity to produce IL-2 or proliferate in response to M. lepraemurium, whereas resistant animals continue these activities (101) . In agreement with these data, lymphoid cells from M. lepraemurium-infected C57BL/6 (resistant) mice secrete more IFNy than cells from CBA (susceptible) animals (213) . In addition, progression of murine leprosy in resistant mice is accompanied by an increment in the number and activity of NK cells. The NK cells, particularly the CD4 + NK1.1 T cells, produce high levels of IFNy and are able to kill mycobacterium-loaded macrophages (53) . By monitoring the CD4 + and CD8 + spleen cell populations in susceptible BALB/c mice infected with M. lepraemurium; a progressive increase in the CD8 + cell population, with no modification in the size of the CD4 + population, has been observed (O. Rojas-Espinosa, unpublished data). As infection leads to death in BALB/c mice, a CD8 + class-2 T cell population is probably the one that increases in the progressive disease. The CD8 + class-2 cells produce type 2 cytokines that exert anti-inflammatory ('suppressive') functions. Another study in favour of a central role for cell-mediated immunity in the control of (murine) leprosy, was reported by Rojas-Espinosa et al. (219) ; mice of a strain of intermediate susceptibility to leprosy (NIH strain) subjected to infection with M. lepraemurium, develop lesions in which macrophage activation ensues in the early stages of the disease. Activated macrophages exhibit a high degree of lysosomal activity, produce high levels of nitric oxide, and show strong mycobactericidal activity. However, this protective, activated state of the macrophages is not sustained, but vanishes as the infection continues, and completely disappears in the more advanced stages of the infection. Proliferation of bacilli is restrained when macrophages are activated, but proliferation occurs once these cells are deactivated. Links between macrophage activation and THl cell activity, and macrophage deactivation and TH2 cell activity have been proposed (216) and on this basis, a study of the role of THl and TH2 cells in murine leprosy is currently underway.
Activation of NK cells in murine leprosy has also been reported. Progressing murine leprosy in C57BL/J (resistant) mice was associated with a sharp increase in splenic NK cell activity, which was abrogated by treatment with a monoclonal antibody against NK cells. Administration of this antibody enhanced C57BL/J susceptibility to murine leprosy as observed by a decrease in survival time of mice infected with 10 Immunotherapy in murine leprosy has been a neglected subject, although infusion of rIL-1 in BALB/c mice infected with M. lepraemurium leads to a reduction in the number of bacilli in liver and lymph nodes of the infused animals (54).
Feline and canine leprosy
Feline leprosy
Although granulomatous skin lesions in cats are not rare, the first report of cat leprosy appears to have been recorded in 1962 in New Zealand (27) .' Since then, cat leprosy has been described in several areas of the world (3, 138, 196, 212, 227, 228, 260, 277) .
All authors described non-encapsulated, granulomatous lesions involving the skin, often with ulceration. In some cases, subepidermis and peripheral lymph nodes were also affected. Sections stained by the Ziehl-Neelsen method revealed large numbers of acid-fast bacilli within macrophages, and attempts to grow the organisms in conventional media for mycobacteria have so far failed. Cat leprosy bacilli passaged in mice have been isolated on 1% Ogawa yolk medium (172) . The isolated bacilli, which were successively cultivated four times on Ogawa medium, produced lepromas in mice. Successful transmission of cat leprosy to laboratory animals has also been reported by Lawrence and Wickham (138) , Poelma and Leiker (196) , and Schiefer and Middleton (228) . The characteristics of the isolated cat leprosy bacillus were identical to those of M. lepraemurium.
The bacilli were slow growing, gave negative test results with heat-resistant catalase, heat-resistant phosphatase, arylsulphatase, niacin, hydrolysis of Tween 80, and urease, and produced light yellowish-white, rough colonies which were rich in coproporphyrin. Thus, on these grounds, cat leprosy bacilli appear to be identical to murine leprosy bacilli.
The similarity of the cat leprosy bacillus to M. lepraemurium was more recently demonstrated by Hughes et al. (102) , using molecular analyses. These authors obtained PCR-amplified 16S ribosomal (r)RNA gene sequences from tissue specimens obtained from eight cats with suspected feline leprosy. Acid-fast bacilli were observed in all eight specimens, but culture of mycobacteria was positive in only one case, (identified as M. avium and M. chitae). The analysis of the V2 variable region of each 16S rRNA PCR product identified a sequence with 100% nucleotide similarity to the sequence of M. lepraemurium in the remaining cases. Molecular analysis therefore provided an accurate and rapid identification of M. lepraemurium as the causative agent of feline leprosy.
Canine leprosy
Although canine leprosy has never been reported, a rare case of indeterminate leprosy developing at the site of a dog bite was reported by Gupta et. al. in India (90) . As leprosy is endemic in India, this was very likely a case of infection with environmental M. leprae, which was facilitated by the dog bite, rather than a case of dog-transmitted leprosy.
Conclusion
While leprosy in wild nine-banded armadillos, chimpanzees, mangabey monkeys and macaques may constitute a zoonosis (273) , murine leprosy appears to be restricted to mice, rats and cats, and is not a zoonosis. Naturally acquired leprosy in other species has not been documented. habituels aux mycobactéries mais il a pu être cultivé dans un milieu à base de jaune d'oeuf. Des cas d'infection naturelle à M. lepraemurium ont également été observés chez les chats; toutefois, la lèpre murine n'affecte ni l'homme, ni aucune autre espèce animale. Ainsi, contrairement à la lèpre humaine, la lèpre murine n'est pas une zoonose. Resumen Mycobacterium leprae, el agente etiológico de la lepra en el hombre, causa una enfermedad granulomatosa crónica que afecta primariamente la piel y los nervios periféricos, y secundariamente algunos órganos internos como los testículos y los ojos; las visceras raramente son afectadas. Dependiendo de la resistencia del huésped, la lepra puede presentarse como una enfermedad benigna (lepra tuberculoide) o como una enfermedad maligna (lepra lepromatosa), pero también puede presentar todo un espectro de formas intermedias. La inmunidad antileprosa depende de la inmunidad mediada por células del huésped y ésta se encuentra severamente deteriorada en la lepra lepromatosa. Aunque M. leprae todavía se mantiene como un microorganismo no cultivable, puede hacerse crecer en varios animales experimentales, incluyendo el armadillo, primates no humanos, y roedores, en cierto grado. Aparte del hombre, la enfermedad adquirida naturalmente se ha encontrado en armadillos silvestres de nueve bandas (Dasypus novemcinctus), en chimpancés (Pan troglodytes), en monos mangabey pardos (Cercocebus atys) y en macacos (Macaca fascicularis). Esto identifica a la lepra como una zoonosis.
Mots-clés
La lepra murina es una enfermedad de las ratas y ratones causada por Mycobacterium lepraemurium. La enfermedad, crónica y granulomatosa, afecta primariamente las visceras y la piel de estos roedores, y esporádicamente los nervios periféricos. Dependiendo de la cepa, la lepra murina puede adquirir las características de la lepra tuberculoide o aquellas de la lepra lepromatosa, y es probable que haya cepas de ratones que desarrollen las formas intermedias de la enfermedad. M. lepraemurium no crece en los medios convencionales para micobacterias pero se ha logrado cultivar en un medio sólido a base de yema de huevo. La lepra murina adquirida naturalmente se ha observado en ratas, ratones y gatos, pero no en el hombre ni en otras especies. Así, contrariamente a la lepra de los humanos, la lepra murina no es una zoonosis.
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